Found 44 articles
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Cybrexa Strengthens Drug Development Capabilities with the Addition of Laurie Kenvin to the Company’s Leadership Team and Nick Saccomano to the SAB
Cybrexa Therapeutics announced the appointments of Laurie Kenvin as Vice President of Clinical Operations and Nick Saccomano, Ph.D., to the Company’s Scientific Advisory Board.
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
Exelixis, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance for full year 2023, and delivered an update on its business.
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
Cybrexa Therapeutics today announced the appointment of Michael N. Needle, MD as Chief Medical Officer.
Modifi Bio Announces Scientific Advisory Board SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trials
Modifi Biosciences , a leader in DNA modification as a novel approach to target cancer, today announced its Scientific Advisory Board, with the appointments of Joseph Costello, PhD; Vishwas Paralkar, PhD; Manmeet Ahluwalia, MD; Peter Glazer, MD, PhD; Jann Sarkaria, MD; Roger Stupp, MD; Michael Dillon, PhD; and Patricia LoRusso, DO.
A combination of Exelixis' cabozantinib and Roche's Tecentriq missed the primary endpoint of overall survival in a Phase III study.
Exelixis has inked a licensing agreement with Catalent to gain access to three of Catalent’s target programs with antibody and ADC candidates, the companies announced Thursday.
Flush with cash from the growing success of its chemotherapy drug, Exelixis dropped $100M on two collaboration deals this week to invest in promising early clinical assets.
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
Exelixis, Inc. and Cybrexa Therapeutics announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12, a clinical-stage, first-in-class peptide-drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
Cybrexa Therapeutics today presented findings as a plenary oral presentation at the annual EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics.
Cybrexa Therapeutics to Present at Upcoming Investor Conferences in June
Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, today announced that the Company’s Chief Executive Officer, Per Hellsund, is scheduled to present at the upcoming conferences.
Unlike antibody-drug conjugates (ADCs) that focus on antigens, PDCs are able to target the tumor microenvironment that has universal features across solid tumors.
Clinical Catch-Up: October 25-29
11/1/2021Yet another busy week for clinical trial news. Here’s a look.
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting
Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, today announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex™-exatecan).
Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Cybrexa Therapeutics announced that it will present the results of a preclinical study of CBX-12, the company’s lead therapeutic candidate for solid tumors, at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 7-10, 2021.
Cybrexa Therapeutics to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference
Cybrexa Therapeutics announced today that management is scheduled to deliver a virtual presentation at the H.C. Wainwright 23rd Annual Global Investment Conference.
Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021
Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that management is scheduled to deliver a company presentation at BTIG Virtual Biotechnology Conference 2021 on Monday, August 9th at 9:00 am ET.
Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR CancerCBX-12 study finds pH selectivity, stability in plasma and selectivity to tumor cells versus healthy tissue
Cybrexa Therapeutics, today announced that NAR Cancer, a fully open access journal publishing original research and survey and summary articles at the intersection of the nucleic acids research and cancer fields, has published a peer-reviewed study of CBX-12, Cybrexa’s lead candidate.
BioSpace Movers & Shakers, May 21
5/21/2021Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.